Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules

Pierre Azoulay ^[1] ; Joshua S Graff Zivin ^[3] ; Danielle Li ^[1] ; Bhaven N. Sampat ^[2]
1. [1] Massachusetts Institute of Technology
  
  Massachusetts Institute of Technology
  
  City of Cambridge, Estados Unidos
2. [2] Columbia University
  
  Columbia University
  
  Estados Unidos
3. [3] National Bureau of Economic Research
Mostrar afiliaciones +
Localización: Review of economic studies, ISSN 0034-6527, Vol. 86, Nº 1, 2019, págs. 117-152
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our article makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant expenditures to private-sector innovations. Second, we take advantage of idiosyncratic rigidities in the rules governing NIH peer review to generate exogenous variation in funding across research areas. Our results show that NIH funding spurs the development of private-sector patents: a $10 million boost in NIH funding leads to a net increase of 2.7 patents. Though valuing patents is difficult, we report a range of estimates for the private value of these patents using different approaches.